Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
-
Stockouts in Argentina threaten continuation of HIV treatments
NewsOne of the costly side-effects of Argentina’s economic crisis is the stockout of essential medicines, with HIV and Hepatitis C...
Read more about Stockouts in Argentina threaten continuation of HIV treatments
-
Connect with us at AIDS 2018 – & increase access to HIV treatment!
NewsAre you going to be at the International AIDS Conference (AIDS2018) in Amsterdam, or following from afar? Here’s how to...
Read more about Connect with us at AIDS 2018 – & increase access to HIV treatment!
-
The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system
OpinionToday’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices, reports Tahir Amin...
-
IP-Watch Q&A with Carlos Correa: The myth of IP incentives for all nations
Interview Q&ADr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property,...
Read more about IP-Watch Q&A with Carlos Correa: The myth of IP incentives for all nations
-
IP-Watch Q&A with Othoman Mellouk: The myth behind health and trade agreements
Interview Q&AOthoman Mellouk is the Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC), and campaign...
Read more about IP-Watch Q&A with Othoman Mellouk: The myth behind health and trade agreements
-
What community activism can achieve – ITPC’s 2017 Annual Review
NewsITPC is proud to share its 2017 Annual Review, titled What Community Activism Can Achieve. The report highlights our successes, challenges, and...
Read more about What community activism can achieve – ITPC’s 2017 Annual Review
-
When will ViiV, Clinton Health and partners officially repair the mistake on missing out 39 countries from the DTG pricing agreement?
Call to action NewsIt has been six months since we alerted the Clinton Health Access Initiative (CHAI) to a glaring omission in the...
-
MMA position on DTG after trials identify potential safety concerns for use at the time of conception
NewsDoultegravir (DTG) is a highly effective, tolerable antiretroviral medicine with a high barrier to resistance; in 2015, WHO recommended it...
-
Five years after the Indian Supreme Court’s Novartis verdict
NewsFive years after this landmark decision, the impact is being felt around the world. India’s decision is frequently held up...
Read more about Five years after the Indian Supreme Court’s Novartis verdict
-